Health care services utilization in patients with ovarian cancer receiving PARP inhibitor maintenance treatment in a US community oncology setting.

Autor: Chase DM; Division of Gynecologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America. Electronic address: dmchase@mednet.ucla.edu., Annavarapu S; Ontada, Irving, TX, USA. Electronic address: Srinivas.Annavarapu@McKesson.com., Tseng WY; Ontada, Irving, TX, USA. Electronic address: Wan-Yu.Tseng@McKesson.com., Shi J; Ontada, Irving, TX, USA. Electronic address: Junxin.Shi@McKesson.com., Szamreta E; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: Elizabeth.Szamreta@Merck.com., Monberg M; Merck & Co., Inc., Rahway, NJ, USA. Electronic address: Matthew.Monberg@Merck.com.
Jazyk: angličtina
Zdroj: Gynecologic oncology [Gynecol Oncol] 2024 Jan; Vol. 180, pp. 79-85. Date of Electronic Publication: 2023 Dec 05.
DOI: 10.1016/j.ygyno.2023.11.016
Abstrakt: Objectives: The objective of this study was to describe healthcare resource use (HCRU) in addition to treatment patterns and discontinuations, in patients with ovarian cancer (OC) initiating PARP inhibitor (PARPi) maintenance treatment in a US community oncology setting.
Methods: This was a retrospective study of patients with OC initiating PARPi monotherapy maintenance during 01/01/2017 to 06/30/2019 (followed until 12/31/2019). Patients aged ≥18 years at first diagnosis of OC with ≥2 visits within The US Oncology Network were included. Structured and chart review data as well as claims data were used to describe treatment patterns and HCRU.
Results: Of the 162 charts reviewed, the median age of patients was 66 years and 80% had stage III or IV disease at diagnosis. In the niraparib, rucaparib and olaparib groups, proportions of patients experiencing dose interruptions were 51%, 50%, and 28%, and discontinuations due to toxicity were 37%, 17% and 15%, respectively. Within the first 6 months, mean numbers of total claims were 43.5, 56.4, and 36.0 in the niraparib, rucaparib, and olaparib groups, and laboratory claims were 13.9, 19.4, and 15.6, respectively. Proportions of patients with hospitalizations (niraparib 40%, rucaparib 32%, olaparib 19%; p = 0.03), also differed as did emergency department visits (niraparib 37%, rucaparib 23%, olaparib 16%; p = 0.02).
Conclusion: Despite patients initiating niraparib having higher rates of dose management events and toxicity-related discontinuations, outpatient and laboratory utilization were similar across all three PARPi. Adequate monitoring of these medications, with differing toxicities, should be emphasized to potentially decrease dose reductions and toxicities.
Competing Interests: Declaration of Competing Interest Dana Chase. Honoraria - AstraZeneca/Merck; Eisai; Genmab/Seattle Genetics; Merck; Tesaro/GSK. Consulting or Advisory Role - AstraZeneca/Merck; Immunogen; Tesaro/GSK. Speakers' Bureau - AstraZeneca/Merck; Eisai; Genmab/Seattle Genetics; Roche; Tesaro/GSK. Research Funding - Genentech (Inst). Uncompensated Relationships - Tesaro/GSK. Srinivas Annavarapu, Junxin Shi, and Wan-Yu Tseng - employees of Ontada. Elizabeth A. Szamreta and Matthew Monberg - employees and ownership of stock, Merck & Co., Inc.
(Copyright © 2023. Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: